0000000000716224

AUTHOR

Felipe Martinez

showing 4 related works from this author

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG …

2017

Background Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non…

MaleARDSdemographyeconomicmedicine.medical_treatmentTerapéuticaair conditioningComorbidityintensive care unitdeveloped country0302 clinical medicineneuromuscular blockingmiddle agedacute myocardial-infarctionmiddle income countryProspective StudiesGeography Medicalcritically-ill patientsadultagedpriority journalrisk factorIncomegeographic-variationDeveloped countryhospitalizationprospective studyHumanPulmonary and Respiratory MedicineDeveloped Countriemedicine.medical_specialtyDeveloping countryArticle/dk/atira/pure/subjectarea/asjc/2700/274003 medical and health sciencesSíndrome respiratorio agudo graveunitsMedicalHumansIntensive care medicineDeveloping CountriesAgedhigh income countryRespiratory Distress Syndrome Adultnoninvasive ventilationAparato respiratoriomedicine.diseasemortalitymajor clinical studyProspective Studiearterial oxygen tension030228 respiratory systemARDSObservational studySociologíahealth care deliverygeographyintensive-careRisk FactorsEpidemiologyProspective cohort studyRespiratory Distress Syndromepartial pressureartificial ventilationSociología médicaMiddle Agedadult respiratory distress syndromeAged; Comorbidity; Delivery of Health Care; Developed Countries; Developing Countries; Europe; Female; Geography Medical; Humans; Income; Intensive Care Units; Male; Middle Aged; Patient Outcome Assessment; Prospective Studies; Respiratory Distress Syndrome Adult; Risk Factors; Pulmonary and Respiratory MedicineEuropeIntensive Care UnitsfemaleincomeFemaleEnfermedadinjurycohort analysigross national incomesurvivalNOmedical geographyDeveloping Countrielength of staymedicinecontrolled studyoutcome assessmentbreast-cancerMechanical ventilationdiseasebusiness.industryDeveloped Countriespatient caredeveloping country030208 emergency & critical care medicinestatistics and numerical data AgedComorbiditywinterACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GEOGRAPHIC-VARIATION; INTENSIVE-CARE; BREAST-CANCER; MORTALITY; DISEASE; INJURY; UNITS; HOSPITALIZATIONPatient Outcome AssessmentEmergency medicineprone positiontreatment outcomebusinessDelivery of Health Care
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE)

2023

Background: Current management practices and outcomes in weaning from invasive mechanical ventilation are poorly understood. We aimed to describe the epidemiology, management, timings, risk for failure, and outcomes of weaning in patients requiring at least 2 days of invasive mechanical ventilation. Methods: WEAN SAFE was an international, multicentre, prospective, observational cohort study done in 481 intensive care units in 50 countries. Eligible participants were older than 16 years, admitted to a participating intensive care unit, and receiving mechanical ventilation for 2 calendar days or longer. We defined weaning initiation as the first attempt to separate a patient from the ventila…

Pulmonary and Respiratory MedicineInternal Medicine SciencesKlinik TıpRESPIRATORY SYSTEMDahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINESağlık BilimleriClinical Medicine (MED)TıpSOLUNUM SİSTEMİMechanical ventilationN/AHealth SciencesSettore MED/41 - ANESTESIOLOGIAAkciğer ve Solunum TıbbıMedicineKlinik Tıp (MED)Chest Diseases and AllergyThe Lancet Respiratory Medicine
researchProduct